Market Size of Glucagon-like Peptide-1 (GLP-1) Agonists Industry
| Study Period | 2019- 2029 |
| Market Size (2024) | USD 11.99 Billion |
| Market Size (2029) | USD 12.63 Billion |
| CAGR (2024 - 2029) | 1.12 % |
| Fastest Growing Market | Middle East and Africa |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Glucagon-like Peptide-1 (GLP-1) Agonists Market Analysis
The Glucagon-like Peptide-1 Agonists Market size is estimated at USD 11.99 billion in 2024, and is expected to reach USD 12.63 billion by 2029, growing at a CAGR of 1.12% during the forecast period (2024-2029).
The COVID-19 pandemic positively impacted the Glucagon-like Peptide-1 (GLP-1) Agonists Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications used for the treatment of type 2 diabetes and some drugs are also approved for obesity. One of the benefits of this class of drugs over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia. Besides being important glucose-lowering agents, GLP-1RAs have significant anti-inflammatory and pulmonary protective effects and an advantageous impact on gut microbes' composition. Therefore, GLP-1RAs have been potential candidates for treating patients affected by COVID-19 infection, with or even without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.
According to International Diabetes Federation (IDF), the adult diabetes population in 2021 is approximately 537 million, and this number is going to increase by 643 million in 2030. Technological advancements have increased over the period leading to several modifications either in the GLP-1RA drug or the formulations being developed.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Glucagon-like Peptide-1 (GLP-1) Agonists Industry Segmentation
GLP-1 receptor agonists are a non-insulin medication combined with diet and exercise to help treat type 2 diabetes. The Glucagon-like Peptide-1 (GLP-1) Agonists Market is segmented into drugs (Dulaglutide(Trulicity), Exenatide (Byetta and Bydureon), Liraglutide (Victoza), Lixisenatide (Lyxumia), and Semaglutide (Ozempic)), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The report offers the value (in USD) and volume (in units) for the above segments. Further, the report will cover a segment-wise breakdown (value and volume) for all the countries covered under the Table of Contents.
| Drugs | ||||
| ||||
| ||||
| ||||
| ||||
|
| Geography | ||||||||||||
| ||||||||||||
| ||||||||||||
| ||||||||||||
| ||||||||||||
|
Glucagon-like Peptide-1 (GLP-1) Agonists Market Size Summary
The Glucagon-like Peptide-1 (GLP-1) Agonists Market is poised for growth, driven by the increasing prevalence of type 2 diabetes and obesity, alongside supportive government initiatives. These medications, which include drugs like Dulaglutide, are pivotal in managing diabetes due to their lower risk of hypoglycemia compared to older treatments and their additional benefits such as weight loss and cardiovascular protection. The market has seen a positive impact from the COVID-19 pandemic, as GLP-1RAs have been recognized for their potential benefits in managing diabetes-related complications and improving immune response. The market landscape is characterized by the presence of major pharmaceutical companies like Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca, which are actively involved in the development and distribution of these therapies globally.
North America currently holds a significant share of the GLP-1 Agonists Market, with a substantial number of adults living with diabetes or prediabetes, particularly among underserved communities. The approval of new formulations, such as the oral GLP-1 agonist Rybelsus, and the introduction of weight loss injections like Wegovy, highlight the ongoing innovation and expansion within the market. These advancements, coupled with the rising demand for effective diabetes management solutions, are expected to sustain the market's growth trajectory over the forecast period. The market's consolidation with key players ensures a competitive environment, fostering further developments and accessibility of GLP-1 therapies across various regions.
Glucagon-like Peptide-1 (GLP-1) Agonists Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.3 Market Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Drugs
-
2.1.1 Dulaglutide
-
2.1.1.1 Trulicity
-
-
2.1.2 Exenatide
-
2.1.2.1 Byetta
-
2.1.2.2 Bydureon
-
-
2.1.3 Liraglutide
-
2.1.3.1 Victoza
-
-
2.1.4 Lixisenatide
-
2.1.4.1 Lyxumia
-
-
2.1.5 Semaglutide
-
2.1.5.1 Ozempic
-
-
-
2.2 Geography
-
2.2.1 North America
-
2.2.1.1 United States
-
2.2.1.2 Canada
-
2.2.1.3 Rest of North America
-
-
2.2.2 Europe
-
2.2.2.1 Germany
-
2.2.2.2 Spain
-
2.2.2.3 Italy
-
2.2.2.4 France
-
2.2.2.5 United Kingdom
-
2.2.2.6 Russia
-
2.2.2.7 Rest of Europe
-
-
2.2.3 Asia-Pacific
-
2.2.3.1 Japan
-
2.2.3.2 China
-
2.2.3.3 Australia
-
2.2.3.4 India
-
2.2.3.5 South Korea
-
2.2.3.6 Malaysia
-
2.2.3.7 Indonesia
-
2.2.3.8 Thailand
-
2.2.3.9 Philippines
-
2.2.3.10 Rest of Asia-Pacific
-
-
2.2.4 Latin America
-
2.2.4.1 Brazil
-
2.2.4.2 Mexico
-
2.2.4.3 Rest of Latin America
-
-
2.2.5 Middle East and Africa
-
2.2.5.1 South Africa
-
2.2.5.2 Saudi Arabia
-
2.2.5.3 Oman
-
2.2.5.4 Egypt
-
2.2.5.5 Iran
-
2.2.5.6 Rest of Middle East and Africa
-
-
-
Glucagon-like Peptide-1 (GLP-1) Agonists Market Size FAQs
How big is the Glucagon-like Peptide-1 Agonists Market?
The Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 11.99 billion in 2024 and grow at a CAGR of 1.12% to reach USD 12.63 billion by 2029.
What is the current Glucagon-like Peptide-1 Agonists Market size?
In 2024, the Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 11.99 billion.
